Alper Topal, Medical Onoclogist at Gülhane Training and Research Hospital, shared a paper Daniel P. Petrylak and colleagues authored on X:
“The Keynote 921 study failed for CRPC.
mPFS was 8.6 months in the pembro arm compared to 8.3 months in the placebo arm.mOS was 19.6 months in the pembro arm compared to 19 months in the placebo arm. Grade 3≥side effects were more common in the pembro arm.”
Authors: Daniel P. Petrylak et al.
